Results 1 to 10 of about 28,670 (189)

Leiomyosarcoma of the Larynx

open access: yesTumori Journal, 2003
Leiomyosarcoma involving the larynx is extremely rare and may be difficult to diagnose. Because of the rarity of this tumor, little information exists on its long-term follow-up and optimal management. We present a review of the literature and report on
Andrea Luigi Cavalot   +4 more
core   +3 more sources

Uterine leiomyosarcoma

open access: yesInternational Journal of Gynecological Cancer
International audienceUterine leiomyosarcoma is a rare and heterogeneous gynecological malignancy that poses a significant clinical challenge due to its aggressive nature and limited treatment options. Its multifactorial etiopathogenesis involves complex
Casali, Paolo   +41 more
core   +5 more sources

On the issue of differential diagnosis of primary vaginal leiomyosarcoma, benign metastatic leiomyoma with transformation of one node into leiomyosarcoma and primary peritoneal leiomyosarcoma

open access: yes, 2023
Differential diagnosis of primary leiomyosarcoma of the vagina/omentum, “benign metastatic leiomyoma” with transformation of one node into leiomyosarcoma, primary peritoneal leiomyosarcoma can present certain difficulties. Due to the rarity of peritoneal
Nikolay V. Khitrov   +4 more
core   +1 more source

Metastases of soft tissue sarcoma to the liver: A Historical Cohort Study from a Hospital‐based Cancer Registry [PDF]

open access: yes, 2020
Background: Hepatic metastasis of soft tissue sarcoma is rare compared to lung metastasis, and the literature is scarce. We examined the risk of hepatic metastasis according to the site of occurrence and histological type.
Harabayashi, Toru   +29 more
core   +1 more source

Cutaneous leiomyosarcoma: dermal and subcutaneous [PDF]

open access: yes, 2020
BACKGROUND AND OBJECTIVES: Leiomyosarcoma of skin (LMS) can be sub-classified on pathology appearances as Dermal or Subcutaneous. The aim of this study was to provide treatment recommendations for these uncommon tumours.
Wong, GN   +7 more
core   +1 more source

LEIOMYOSARCOMA OF THE MAXILLARY GINGIVA: A CASE REPORT [PDF]

open access: yes, 1995
1995-12-25An unusual case of leiomyosarcoma (LMS) of the maxillary gingiva is discussed here; this case presents a unique pattern of tumor growth and a long period between initial discovery and correct pathological diagnosis.
MIZUTANI, HIDEKI   +3 more
core   +1 more source

Renal Leiomyosarcoma

open access: yesRare Tumors, 2013
Leiomyosarcoma (LMS) is a rare malignant tumor of smooth muscle origin that generally stems from soft tissues and uterine tissue. Although, a small percentage of these may originate from the smooth muscle or vessel walls, most of which are of venous origin.
Pastora Beardo   +2 more
openaire   +3 more sources

Primary leiomyosarcoma of the vulva – a  rare occurrence

open access: yes, 2023
Vulval tumours are rare, representing merely 4% of all gynaecological neoplasms. 98% of vulvar lesions are benign, and only 2% are malignant. Of all vulvar malignancies, while squamous cell carcinoma is the most common malignancy, leiomyosarcomas of the ...
Anju Singh   +3 more
core   +1 more source

Leiomyosarcoma With Alternative Lengthening of Telomeres Is Associated With Aggressive Histologic Features, Loss of ATRX Expression, and Poor Clinical Outcome

open access: yes, 2017
Leiomyosarcoma is an aggressive soft tissue sarcoma with poor patient survival. Recently, it was shown that 53% to 62% of leiomyosarcomas use the alternative lengthening of telomeres (ALT) as their telomere maintenance mechanism.
Liau, Jau-Yu;Tsai, Jia-Huei;Jeng, Yung-Ming;Lee, Jen-Chieh;Hsu, Hung-Han;Yang, Ching-Yao   +1 more
core   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Home - About - Disclaimer - Privacy